Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Restriction Enzyme Cleavage Site	NCIT_C54667	[The specific DNA base that is cut by a specific restriction enzyme.]
CpG Island	NCIT_C54668	[Short region of DNA in which the frequency of the CG sequence is higher than in other regions.]
Gene Feature	NCIT_C13445	[The structural elements that comprise a gene or transcription unit. Gene structures include the transcription initiation site, the protein coding sequences, intervening sequences, and the transcription termination or polyadenylation sites as well as the regulatory elements (enhancers, silencers, and the promoter) that lie outside the boundaries of the transcribed unit.]
Overlap	NCIT_C54669	[The phenomenon of coinciding partially or wholly; extending over and covering a part of.]
7-Alpha-Hydroxycholest-4-En-3-One 12-Alpha-Hydroxylase	NCIT_C40055	[7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase (501 aa, ~58 kDa) is encoded by the human CYP8B1 gene. This protein is involved in bile acid biosynthesis and steroid metabolism.]
CYP11A1 Gene	NCIT_C40056	[This gene is involved in steroid metabolism.]
Oxidation	NCIT_C16944	[The process of oxidizing; the addition of oxygen to a compound accompanied by a loss of electrons.]
Cholesterol Side-Chain Cleavage Enzyme, Mitochondrial	NCIT_C40057	[Cholesterol side-chain cleavage enzyme, mitochondrial (521 aa, ~60 kDa) is encoded by the human CYP11A1 gene. This protein plays a role in the catalysis of the side-chain cleavage reaction converting cholesterol to pregnenolone.]
CYP11B1 Gene	NCIT_C40058	[This gene plays a role in the metabolism of glucucorticoids.]
Adrenal Cortical Hyperplasia	NCIT_C3506	[Congenital or acquired hyperplasia of the cells of the adrenal cortex.]
Cytochrome P450 CYP11B1, Mitochondrial	NCIT_C40059	[Cytochrome P450 CYP11B1, mitochondrial (503 aa, ~58 kDa) is encoded by the human CYP11B1 gene. This protein plays a role in steroid biosynthesis and metabolism.]
Ovarian Endometrioid Adenocarcinofibroma	NCIT_C40060	[A malignant neoplasm of the ovary characterized by the presence of malignant glandular cells resembling endometrial cells in a fibrotic stroma.]
Ovarian Endometrioid Adenocarcinoma with Squamous Differentiation	NCIT_C40061	[An endometrioid adenocarcinoma that arises from the ovary and exhibits squamous differentiation. The squamous cell component often has a cytologically benign appearance.]
Endometrioid Adenocarcinoma, Variant with Squamous Differentiation	NCIT_C158610	[An endometrioid adenocarcinoma exhibiting squamous differentiation.]
CYP11B2 Gene	NCIT_C40062	[This gene is involved in mineralocorticoid metabolism.]
Ovarian Low Grade Endometrioid Stromal Sarcoma	NCIT_C40063	[A rare invasive mesenchymal tumor that arises from the ovary. It is characterized by the absence of marked pleomorphism and nuclear atypia in the neoplastic mesenchymal cells. It may have a favorable clinical outcome.]
Ovarian Endometrioid Stromal and Related Neoplasms	NCIT_C40065	[A category of rare neoplasms that arise from the ovary. It includes low grade endometrioid stromal sarcoma and undifferentiated sarcoma.]
Cytochrome P450 11B2, Mitochondrial	NCIT_C40064	[Cytochrome P450 11B2, mitochondrial (503 aa, ~58 kDa) is encoded by the human CYP11B2 gene. This protein plays a role in corticosterone metabolism.]
Ovarian Soft Tissue Neoplasm	NCIT_C5244	[A benign or malignant soft tissue neoplasm of the ovary. Representative examples include myxoma, fibroma, and sarcoma.]
Combination Product	NCIT_C54696	[A product comprised of two or more regulated components, i.e., drug and device, biologic and device, that are physically, chemically, or otherwise combined or mixed and produced as a single entity; or two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; or a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.]